No One Said It Would Be Easy
Released Monday night, the Senate majority’s proposed FY27 spending bills include a $500 million increase for NIH, but fail to address a looming threat to medical progress. As our release pointed out, none of the five bills would stop or further delay a proposed Office of Management and Budget (OMB) rule that would make it easier to terminate research grants and lifesaving clinical trials for political reasons. In their coverage of these bills and the OMB rule, both Politico and Inside Higher Ed quoted Russ.
The stakes are immediate. An existing congressional provision blocking OMB from finalizing the rule expires on Dec. 11. Without further action by Congress, OMB could move forward. That’s why we’re working with a broad coalition of patient organizations, cities, counties, universities, Tribal Nations, farmers, and businesses in urging Congress to extend the prohibition and prevent scientific and medical research from becoming a political football. No one said stopping this rule would be easy. Don’t sit on the sidelines: email your members of Congress now.
Russ’s Corner
Each week seems to bring more headlines about “brain drain,” fewer pathways to STEMM careers, and restrictions on international students who contribute to our nation’s scientific advancement. Coupled with increased research spending in other countries, these developments raise questions about America’s ability to maintain its position at the forefront of scientific discovery.
While some threats to science and research are clear on their face (e.g., the harmful proposed rule from OMB) other developments present more nuanced questions. Last year, Congress passed the Comprehensive Outbound Investment National Security (COINS) Act to prevent certain U.S. investments from supporting the development of certain technologies in “countries of concern” that could threaten American national security.
Late last month, the U.S. Department of the Treasury proposed a rule to implement the COINS Act that would expand the scope of the law to include biotechnology. Including biotechnology within the scope of the law makes sense. The potential national security risks in this arena warrant vigilance. At the same time, the intersection of national security, U.S.-China competitiveness, and medical progress is complex. There are many rabbit holes, many potential unintended consequences.
Sorting through all of these complexities is where Research!America can play an important role. We’re partnering with Friends of Cancer Research, the American Institute for Medical and Biological Engineering, and the Engineering Biology Research Consortium to host a webinar on Tuesday, Dec. 1, from 11 a.m. to 12 p.m. ET, to help stakeholders better understand the proposed rule; its potential implications for academic research, patients, and the biomedical R&D pipeline; and the broader policy considerations at stake. RSVP today using this link. Bringing diverse perspectives together to illuminate complex issues affecting medical progress is what our alliance does best, and we look forward to your participation. Stay tuned for additional details, and I hope you’ll join us for this important discussion!
Russ
Agency Nominations – Advocacy Matters: The Senate Health, Education, Labor, and Pensions (HELP) Committee was scheduled to vote yesterday on two consequential nominations: Heidi Overton, M.D., to lead the FDA (the administration withdrew her nomination on Tuesday evening), and James O’Neill to lead the National Science Foundation (NSF).
Research!America urged the committee not to advance O’Neill’s nomination without first holding a public hearing, giving senators and the public an opportunity to hear his vision for this critically important agency. Other important voices from the scientific community played an outspoken advocacy role as well. Ultimately, HELP Committee Chair Sen. Bill Cassidy (R-LA) canceled the vote on O’Neill Wednesday morning.
Update on the GAO Comptroller Nomination: Research!America sent this letter to leaders of the Senate Committee on Homeland Security and Governmental Affairs (Senate HSGAC) urging the committee to postpone consideration of a Government Accountability Office (GAO) Comptroller nominee until a more thorough, bipartisan, and deliberative process has been completed. Senate HSGAC held a hearing today on President Trump’s nominee, current OMB Deputy Director Eric Ueland, but neither the Chair nor Ranking Member indicated whether there will be a future vote on the nomination.
Civic Science Deadline Extended: The application deadline for our Civic Science Microgrants and Awards Program has been extended to Monday, Nov. 30. Don’t miss this funding opportunity! Each year, we award microgrants up to $4,000 to groups of early-career researchers who have innovative ideas that connect scientists with public audiences through community-focused projects. There are also individual awards up to $5,000 for developing open-access curricula that strengthen scientists’ public engagement skills. Send in your applications today!
Join Research!America: If you haven’t already, join our multi-sector alliance! The membership process is straightforward, the benefits are compelling, and your participation informs and intensifies our community’s influence on and off Capitol Hill. Email Associate Director of Membership and Development Operations Donald Cook for more information.

